Home LiteratureArticle Details
PMID: 1507401 Published · ppublish jpn Clinical Trial Controlled Clinical Trial Journal Article Multicenter Study

[Pharmacokinetic and clinical studies with meropenem in the pediatric field. Pediatric Study Group of Meropenem].

The Japanese journal of antibiotics ·Vol. 45 ·No. 6 ·1992-06-00 ·Pages 697-717

Fujii R, Yoshioka H, Fujita K, Maruyama S, Sakata H, Inyaku F, Chiba S, Tsutsumi H, Wagatsuma Y, Fukushima N

Abstract

Pharmacokinetic and clinical evaluations in pediatrics were made on meropenem (SM-7338, MEPM), a new parenteral dehydropeptidase-1 stable carbapenem used without any inhibitors, at 33 medical institutions. The results are summarized as follows. 1. Pharmacokinetic studies. MEPM at a dose of 10, 20, or 40 mg/kg was administered to 53 children by 30-minute drip infusion. Peak plasma concentrations (Cmax's) and plasma half-lives (T1/2's) of these doses were 28.5, 47.2 and 130.0 micrograms/ml, and 0.80, 0.93 and 0.94 hours, respectively. A clear dose response was observed in Cmax's and T1/2 values were quite similar to those observed in adults. In the first 6 hours after administration, 54.4 to 68.1% of the administered drug was recovered in urine. The cerebrospinal fluid (CSF) levels of MEPM in patients with purulent meningitis were 0.13 microgram/ml at a dose of 6 mg/kg, and 0.64 to 4.22 micrograms/ml at a dose of 29 to 44 mg/kg within day 4 of onset. The penetration rate of MEPM showed an intermediate value among those for other cephalosporin antibiotics. 2. Clinical study. Clinical efficacies of MEPM were evaluated in 389 cases. The most common doses used were 10 to 20 mg/kg/once, 2 to 3 times a day. The maximum dose was 173 mg/kg/day q.i.d. MEPM gave "excellent" or "good" responses in 242 (97.6%) out of 248 cases in which causative organisms were documented and in 134 (95.0%) out of 141 cases in which causative organisms were not identified. Clinical efficacy rates were 100% in 11 patients with purulent meningitis, 85.7% in 7 with septicemia, 98.8% in 173 with pneumonia, and 100% in 65 with UTI. Bacteriologically, 260 strains (96.7%) out of 269 strains were eradicated by MEPM treatment. Eradication rates were 89.2% for Staphylococcus aureus (37 strains) and 100% for Streptococcus pneumoniae (35 strains). The overall eradication rate for Gram-positive bacteria was 94.6%. Among Gram-negative bacteria, 98.3% out of 172 strains were eradicated. The eradication rate of Haemophilus influenzae (73 strains) was 98.6% and Pseudomonas aeruginosa (11 strains) was 90.9%, and all of Branhamella catarrhalis (15 strains), Escherichia coli (42 strains), and Klebsiella pneumoniae (6 strains) were eradicated. Out of 84 cases for which previous antibiotic therapies of 3 days or longer were not successful, MEPM gave "excellent" or "good" responses in 77 cases (91.7%) and excellent bacteriological responses (95.7%).(ABSTRACT TRUNCATED AT 400 WORDS)

MeSH Terms
Bacterial Infections/drug therapy Child Child, Preschool Escherichia coli Infections/drug therapy Female Haemophilus Infections/drug therapy Haemophilus influenzae Humans Infant Klebsiella Infections/drug therapy Klebsiella pneumoniae Male Meropenem Moraxella catarrhalis Neisseriaceae Infections/drug therapy Pseudomonas Infections/drug therapy Staphylococcal Infections/drug therapy Streptococcal Infections/drug therapy Thienamycins/adverse effects,pharmacokinetics,therapeutic use
Chemicals
Thienamycins Meropenem
Authors & Affiliations
10 authors, click to expand affiliations / ORCID
Fujii R
Department of Pediatrics, School of Medicine, Teikyo University.
Yoshioka H
Fujita K
Maruyama S
Sakata H
Inyaku F
Chiba S
Tsutsumi H
Wagatsuma Y
Fukushima N
Article Info
Journal
The Japanese journal of antibiotics
Abbr.
Jpn J Antibiot
ISSN
0368-2781
Published
1992-06-00
Pages
697-717
Language
jpn
Region
Japan
NLM ID
0154402
Subset
IM
External Links
PubMed source
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]